136 related articles for article (PubMed ID: 36943203)
1. Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care.
DE Bastiani R; Lopetuso LR; DE Bastiani M; Bacchin P; Benedetto E; Boscariolo L; Caneve R; Chesani F; Chiumeo F; Civic Z; Dainese A; DE Polo M; Disclafani G; Grattagliano I; Mana O; Mancuso M; Mastronuzzi T; Pati A; Pirrotta E; Salandini M; Sanna G; Scoglio R; Severino P; Tosetti C; Turnava L; Zamparella M; Elisei W; Gasbarrini A; Tursi A
Minerva Gastroenterol (Torino); 2023 Dec; 69(4):523-528. PubMed ID: 36943203
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
3. [The effects of continuous proton pump inhibitor therapy on small intestinal bacterial overgrowth in elderly].
Zhang R; Li Y; Ma JX; Tang S; Li CM; Wan J
Zhonghua Nei Ke Za Zhi; 2020 Sep; 59(9):706-710. PubMed ID: 32838502
[No Abstract] [Full Text] [Related]
4. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.
Lombardo L; Foti M; Ruggia O; Chiecchio A
Clin Gastroenterol Hepatol; 2010 Jun; 8(6):504-8. PubMed ID: 20060064
[TBL] [Abstract][Full Text] [Related]
5. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.
Chedid V; Dhalla S; Clarke JO; Roland BC; Dunbar KB; Koh J; Justino E; Tomakin E; Mullin GE
Glob Adv Health Med; 2014 May; 3(3):16-24. PubMed ID: 24891990
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth.
Ratuapli SK; Ellington TG; O'Neill MT; Umar SB; Harris LA; Foxx-Orenstein AE; Burdick GE; Dibaise JK; Lacy BE; Crowell MD
Am J Gastroenterol; 2012 May; 107(5):730-5. PubMed ID: 22334250
[TBL] [Abstract][Full Text] [Related]
7. Preferential usage of rifaximin for the treatment of hydrogen-positive smallintestinal bacterial overgrowth.
Barkin JA; Keihanian T; Barkin JS; Antequera CM; Moshiree B
Rev Gastroenterol Peru; 2019; 39(2):111-115. PubMed ID: 31333225
[TBL] [Abstract][Full Text] [Related]
8. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors
Revaiah PC; Kochhar R; Rana SV; Berry N; Ashat M; Dhaka N; Rami Reddy Y; Sinha SK
JGH Open; 2018 Apr; 2(2):47-53. PubMed ID: 30483563
[TBL] [Abstract][Full Text] [Related]
9. Association between chronic use of proton pump inhibitors and small- intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests.
Fujiwara Y; Watanabe T; Muraki M; Yamagami H; Tanigawa T; Shiba M; Tominaga K; Arakawa T
Hepatogastroenterology; 2015; 62(138):268-72. PubMed ID: 25916046
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS.
Law D; Pimentel M
Dig Dis Sci; 2010 Aug; 55(8):2302-8. PubMed ID: 19834807
[TBL] [Abstract][Full Text] [Related]
11. Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit.
Suri J; Kataria R; Malik Z; Parkman HP; Schey R
Medicine (Baltimore); 2018 May; 97(21):e10554. PubMed ID: 29794732
[TBL] [Abstract][Full Text] [Related]
12. [Association of food patterns with different forms of small intestinal bacterial overgroth syndrome and treatment efficacy].
Pilipenko VI; Isakov VA; Morozov SV; Vlasova AV; Naydenova MA
Ter Arkh; 2019 Oct; 91(10):82-90. PubMed ID: 32598636
[TBL] [Abstract][Full Text] [Related]
13. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.
Furnari M; De Alessandri A; Cresta F; Haupt M; Bassi M; Calvi A; Haupt R; Bodini G; Ahmed I; Bagnasco F; Giannini EG; Casciaro R
J Gastroenterol; 2019 Mar; 54(3):261-270. PubMed ID: 30232597
[TBL] [Abstract][Full Text] [Related]
14. Breath hydrogen and methane are associated with intestinal symptoms in patients with chronic pancreatitis.
Kim DB; Paik CN; Sung HJ; Chung WC; Lee KM; Yang JM; Choi MG
Pancreatology; 2015; 15(5):514-518. PubMed ID: 26278025
[TBL] [Abstract][Full Text] [Related]
15. Small Intestinal Transit Time Is Delayed in Small Intestinal Bacterial Overgrowth.
Roland BC; Ciarleglio MM; Clarke JO; Semler JR; Tomakin E; Mullin GE; Pasricha PJ
J Clin Gastroenterol; 2015 Aug; 49(7):571-6. PubMed ID: 25319735
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lactulose and glucose breath test for diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome.
Rana SV; Sharma S; Kaur J; Sinha SK; Singh K
Digestion; 2012; 85(3):243-7. PubMed ID: 22472730
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI).
Ní Chonchubhair HM; Bashir Y; Dobson M; Ryan BM; Duggan SN; Conlon KC
Pancreatology; 2018 Jun; 18(4):379-385. PubMed ID: 29502987
[TBL] [Abstract][Full Text] [Related]
18. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Majewski M; McCallum RW
Adv Med Sci; 2007; 52():139-42. PubMed ID: 18217406
[TBL] [Abstract][Full Text] [Related]
19. The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth.
Gabbard SL; Lacy BE; Levine GM; Crowell MD
Dig Dis Sci; 2014 Mar; 59(3):638-44. PubMed ID: 24323179
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Small Intestinal Bacterial Overgrowth and Symptoms After 7 Days of Proton Pump Inhibitor Use: A Study on Healthy Volunteers.
Durán-Rosas C; Priego-Parra BA; Morel-Cerda E; Mercado-Jauregui LA; Aquino-Ruiz CA; Triana-Romero A; Amieva-Balmori M; Velasco JAV; Remes-Troche JM
Dig Dis Sci; 2024 Jan; 69(1):209-215. PubMed ID: 37910339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
